Abbott s Pending Acquisition of Vysis Clears Antitrust Hurdles | GenomeWeb

NEW YORK, Nov. 23 - Abbott Laboratories' $355 million acquisition of Vysis came one step closer to closing on Friday as the Hart-Scott- Rodino Antitrust Improvements Act waiting period expired.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.